{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Magnetic+resonance+spectroscopy+%28MRS%29&page=17", "query": { "intervention": "Magnetic resonance spectroscopy (MRS)", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 1722, "total_pages": 173, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Magnetic+resonance+spectroscopy+%28MRS%29&page=18&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Magnetic+resonance+spectroscopy+%28MRS%29&page=16&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T17:36:56.291Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04739800", "title": "Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Mucinous Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Platinum-Refractory Fallopian Tube Carcinoma", "Platinum-Refractory Ovarian Carcinoma", "Platinum-Refractory Primary Peritoneal Carcinoma", "Recurrent Fallopian Tube Clear Cell Adenocarcinoma", "Recurrent Fallopian Tube Endometrioid Adenocarcinoma", "Recurrent Fallopian Tube High Grade Serous Adenocarcinoma", "Recurrent Fallopian Tube Mucinous Adenocarcinoma", "Recurrent Fallopian Tube Transitional Cell Carcinoma", "Recurrent Fallopian Tube Undifferentiated Carcinoma", "Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma", "Recurrent Ovarian Clear Cell Adenocarcinoma", "Recurrent Ovarian Endometrioid Adenocarcinoma", "Recurrent Ovarian High Grade Serous Adenocarcinoma", "Recurrent Ovarian Low Grade Serous Adenocarcinoma", "Recurrent Ovarian Mucinous Adenocarcinoma", "Recurrent Ovarian Seromucinous Carcinoma", "Recurrent Ovarian Transitional Cell Carcinoma", "Recurrent Ovarian Undifferentiated Carcinoma", "Recurrent Platinum-Resistant Fallopian Tube Carcinoma", "Recurrent Platinum-Resistant Ovarian Carcinoma", "Recurrent Platinum-Resistant Primary Peritoneal Carcinoma", "Recurrent Primary Peritoneal Clear Cell Adenocarcinoma", "Recurrent Primary Peritoneal Endometrioid Adenocarcinoma", "Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma", "Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma", "Recurrent Primary Peritoneal Transitional Cell Carcinoma", "Recurrent Primary Peritoneal Undifferentiated Carcinoma", "Refractory Fallopian Tube Clear Cell Adenocarcinoma", "Refractory Fallopian Tube Endometrioid Adenocarcinoma", "Refractory Fallopian Tube High Grade Serous Adenocarcinoma", "Refractory Fallopian Tube Mucinous Adenocarcinoma", "Refractory Fallopian Tube Transitional Cell Carcinoma", "Refractory Fallopian Tube Undifferentiated Carcinoma", "Refractory Low Grade Fallopian Tube Serous Adenocarcinoma", "Refractory Ovarian Clear Cell Adenocarcinoma", "Refractory Ovarian Endometrioid Adenocarcinoma", "Refractory Ovarian High Grade Serous Adenocarcinoma", "Refractory Ovarian Low Grade Serous Adenocarcinoma", "Refractory Ovarian Mucinous Adenocarcinoma", "Refractory Ovarian Seromucinous Carcinoma", "Refractory Ovarian Transitional Cell Carcinoma", "Refractory Ovarian Undifferentiated Carcinoma", "Refractory Primary Peritoneal Clear Cell Adenocarcinoma", "Refractory Primary Peritoneal Endometrioid Adenocarcinoma", "Refractory Primary Peritoneal High Grade Serous Adenocarcinoma", "Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma", "Refractory Primary Peritoneal Transitional Cell Carcinoma", "Refractory Primary Peritoneal Undifferentiated Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cediranib Maleate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Computed Tomography with Contrast", "type": "PROCEDURE" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pegylated Liposomal Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Topotecan Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 120, "start_date": "2021-06-10", "completion_date": "2027-06-25", "has_results": true, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-15T17:36:56.291Z", "location_count": 384, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 288 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04739800" }, { "nct_id": "NCT02154711", "title": "Magnetic Resonance Imaging (MRI) Muscle Phenotyping in Mitochondrial Disease", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Mitochondrial Disease" ], "interventions": [], "intervention_types": [], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 40, "start_date": "2014-05", "completion_date": "2020-06-30", "has_results": false, "last_update_posted_date": "2024-08-29", "last_synced_at": "2026-10-15T17:36:56.291Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02154711" }, { "nct_id": "NCT01610011", "title": "Acute Glycine Pharmacodynamic Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Schizophrenia", "Psychotic Disorders" ], "interventions": [ { "name": "Glycine administration", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Mclean Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 21, "start_date": "2010-07", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2015-10-27", "last_synced_at": "2026-10-15T17:36:56.291Z", "location_count": 1, "location_summary": "Belmont, Massachusetts", "locations": [ { "city": "Belmont", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01610011" }, { "nct_id": "NCT06351371", "title": "Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Erdafitinib", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2018-07-03", "completion_date": "2027-01-15", "has_results": true, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-15T17:36:56.291Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06351371" }, { "nct_id": "NCT04752267", "title": "18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Glioma", "Malignant Brain Neoplasm", "Metastatic Breast Carcinoma", "Metastatic Colon Carcinoma", "Metastatic Kidney Carcinoma", "Metastatic Lung Carcinoma", "Metastatic Malignant Neoplasm in the Brain", "Metastatic Melanoma", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8", "Stage IV Colon Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVA Colon Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Colon Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Stage IVC Colon Cancer AJCC v8" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "18F-FMAU", "type": "DRUG" }, { "name": "Multiparametric Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2021-02-15", "completion_date": "2023-09-18", "has_results": false, "last_update_posted_date": "2024-05-24", "last_synced_at": "2026-10-15T17:36:56.291Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04752267" }, { "nct_id": "NCT07224100", "title": "Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1", "B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1", "Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Ponatinib", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2026-03-30", "completion_date": "2028-07-31", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-15T17:36:56.291Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07224100" }, { "nct_id": "NCT07293247", "title": "A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Non-Small Cell Carcinoma" ], "interventions": [ { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Immunotherapy", "type": "OTHER" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION", "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 164, "start_date": "2026-10-14", "completion_date": "2032-03-01", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-15T17:36:56.291Z", "location_count": 111, "location_summary": "Jonesboro, Arkansas • Los Angeles, California • Parker, Colorado + 83 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Parker", "state": "Colorado" }, { "city": "Bloomington", "state": "Illinois" }, { "city": "Bloomington", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07293247" }, { "nct_id": "NCT06126276", "title": "Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Female Reproductive System Neoplasm", "Malignant Solid Neoplasm", "Recurrent Malignant Female Reproductive System Neoplasm", "Recurrent Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Neratinib Maleate", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2024-05-07", "completion_date": "2027-02-20", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-15T17:36:56.291Z", "location_count": 193, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 154 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06126276" }, { "nct_id": "NCT02429804", "title": "NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hormone-Resistant Prostate Cancer", "Metastatic Malignant Neoplasm in the Bone", "Metastatic Prostate Carcinoma" ], "interventions": [ { "name": "Contrast-enhanced Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "DRUG" }, { "name": "Fluorine F 18 Sodium Fluoride", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "MALE", "summary": "19 Years and older · Male only" }, "enrollment_count": 4, "start_date": "2015-04", "completion_date": "2017-05-15", "has_results": false, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-10-15T17:36:56.291Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02429804" }, { "nct_id": "NCT07322341", "title": "SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lung Non-Small Cell Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "CXCR1/2 Inhibitor SX-682", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2026-10-06", "completion_date": "2031-11-01", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-15T17:36:56.291Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07322341" } ] }